TEVOGEN BIO HOLDINGS INC (TVGN) Stock News
NASDAQ:TVGN - Nasdaq - US88165K1016 - Common Stock - Currency: USD
TVGN Latest News, Press Relases and Analysis
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings...
Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential
D Boral Capital initiates Buy on Tevogen Bio citing its scalable T-cell therapies and upcoming clinical readouts, with a $10 price target.
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Mentions: MSFT
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Tevogen Bio will receive the remaining $8 million grant, totaling $10 million, from KRHP LLC this quarter, following a positive review of its progress,...
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Tevogen Bio is focused on delivering affordable, safe, and easy-to-administer T cell therapies.The company’s ExacTcell™ technology enabled a...
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen’s model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability.
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”)...
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty...
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
Mentions: MSFT
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
CEO of Tevogen Bio, Dr. Saadi addresses short selling and its potential impact on the nation’s health and prosperity. Reaffirms commitment to...
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
WARREN, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:...
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty...
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty...
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
Mentions: MSFT
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
The grant funding will further Tevogen Bio’s mission to develop therapies for treatment of cancers and viral infections.Tevogen Bio may also utilize the...
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
WARREN, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Dr. Ryan Saadi, Chairman and founding CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”)...
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
Mentions: MSFT
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for...
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Mentions: MSFT
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty...
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders,...
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
Mentions: MSFT
Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference
WARREN, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty...